DE69631544D1 - Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse - Google Patents

Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse

Info

Publication number
DE69631544D1
DE69631544D1 DE69631544T DE69631544T DE69631544D1 DE 69631544 D1 DE69631544 D1 DE 69631544D1 DE 69631544 T DE69631544 T DE 69631544T DE 69631544 T DE69631544 T DE 69631544T DE 69631544 D1 DE69631544 D1 DE 69631544D1
Authority
DE
Germany
Prior art keywords
body mass
lean body
increase lean
obesity protein
increasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69631544T
Other languages
English (en)
Other versions
DE69631544T2 (de
Inventor
Ann Pelleymounter
Francis Toombs
Michael Benjamin Mann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DE69631544D1 publication Critical patent/DE69631544D1/de
Application granted granted Critical
Publication of DE69631544T2 publication Critical patent/DE69631544T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69631544T 1995-11-22 1996-11-04 Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse Expired - Lifetime DE69631544T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56173295A 1995-11-22 1995-11-22
US561732 1995-11-22
PCT/US1996/017718 WO1997018833A1 (en) 1995-11-22 1996-11-04 Methods of increasing lean tissue mass using ob protein compositions

Publications (2)

Publication Number Publication Date
DE69631544D1 true DE69631544D1 (de) 2004-03-18
DE69631544T2 DE69631544T2 (de) 2004-12-23

Family

ID=24243198

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69631544T Expired - Lifetime DE69631544T2 (de) 1995-11-22 1996-11-04 Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
DE69638119T Expired - Lifetime DE69638119D1 (de) 1995-11-22 1996-11-04 Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69638119T Expired - Lifetime DE69638119D1 (de) 1995-11-22 1996-11-04 Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen

Country Status (15)

Country Link
EP (3) EP0956862A1 (de)
JP (2) JP4173914B2 (de)
AT (2) ATE455554T1 (de)
AU (3) AU7607496A (de)
CA (2) CA2358862A1 (de)
DE (2) DE69631544T2 (de)
DK (1) DK0866720T3 (de)
ES (2) ES2217327T3 (de)
IL (2) IL124442A0 (de)
MX (1) MX9803992A (de)
NZ (3) NZ512083A (de)
PT (1) PT866720E (de)
SI (1) SI0866720T1 (de)
WO (1) WO1997018833A1 (de)
ZA (1) ZA969605B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
PT866720E (pt) * 1995-11-22 2004-06-30 Amgen Inc Proteina ob para aumentar a massa do tecido mole
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
JP2000505791A (ja) * 1996-01-25 2000-05-16 イーライ・リリー・アンド・カンパニー 肥満症タンパク質類似体化合物およびその製剤
EP0917469A1 (de) * 1996-04-19 1999-05-26 ZymoGenetics, Inc. Verfahren zur induzierung der knochenbildung
AU5802898A (en) * 1996-12-20 1998-07-17 Eli Lilly And Company Anti-obesity proteins
NZ514145A (en) * 1996-12-20 2003-08-29 Amgen Inc OB fusion protein compositions and methods
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
EP0950417A3 (de) 1998-02-23 2000-02-23 Pfizer Products Inc. Behandlung von Skeletterkrankungen
WO1999053939A1 (en) * 1998-04-20 1999-10-28 Mayo Foundation For Medical Education And Research Treatment of osteoporosis with leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
WO2000024418A1 (en) * 1998-10-27 2000-05-04 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
JP4841037B2 (ja) * 1999-02-12 2011-12-21 アムジエン・インコーポレーテツド グリコシル化レプチン組成物および関連する方法
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
DK2219031T3 (da) 2001-10-22 2013-06-17 Amgen Inc Anvendelse af leptin til behandling af human lipoatrofi og fremgangsmåde til bestemmelse af prædisposition for behandlinngen
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
JP2008505119A (ja) * 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション 高分子−第ｉｘ因子部分の抱合体
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2286840A3 (de) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Behandlung von Fettleibigkeit und von verwandten Krankheiten
WO2008048691A2 (en) * 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
US8501686B2 (en) 2008-06-05 2013-08-06 University Of Michigan Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
PT2621519T (pt) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
LT2900230T (lt) 2012-09-27 2019-01-10 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
TR201901299T4 (tr) 2013-11-26 2019-02-21 Childrens Medical Ct Corp Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri.
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
RS64850B1 (sr) 2016-09-12 2023-12-29 Amryt Pharmaceuticals Inc Metodi za detektovanje neutrališućih antitela na leptin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228925B (it) * 1987-08-07 1991-07-10 Eniricerche Spa Procedimento per la preparazione dell'ormone della crescita umano
DK173142B1 (da) * 1988-08-24 2000-02-07 Natinco Nv Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
EP0765271B1 (de) * 1993-08-13 1998-05-13 PUTZMEISTER Aktiengesellschaft Verfahren und anordnung zur oberflächenbearbeitung von grossobjekten
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
PT866720E (pt) * 1995-11-22 2004-06-30 Amgen Inc Proteina ob para aumentar a massa do tecido mole
CA2238307A1 (en) * 1995-12-27 1997-07-10 Genentech, Inc. Ob protein derivatives having prolonged half-life
NZ514145A (en) * 1996-12-20 2003-08-29 Amgen Inc OB fusion protein compositions and methods
JP4086908B2 (ja) * 1997-04-17 2008-05-14 アムジエン・インコーポレーテツド 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法

Also Published As

Publication number Publication date
EP0956862A1 (de) 1999-11-17
JP2002206000A (ja) 2002-07-23
NZ512083A (en) 2003-02-28
EP1285664A3 (de) 2003-07-30
AU4265200A (en) 2000-09-21
ZA969605B (en) 1997-06-02
JP4227325B2 (ja) 2009-02-18
NZ511617A (en) 2003-08-29
IL127926A0 (en) 1999-11-30
CA2236163A1 (en) 1997-05-29
IL127926A (en) 2006-08-20
DK0866720T3 (da) 2004-06-14
JP4173914B2 (ja) 2008-10-29
EP0866720B1 (de) 2004-02-11
AU763755B2 (en) 2003-07-31
ES2339846T3 (es) 2010-05-26
AU7607496A (en) 1997-06-11
AU4265300A (en) 2000-09-07
SI0866720T1 (en) 2004-10-31
AU763769B2 (en) 2003-07-31
IL124442A0 (en) 1998-12-06
ATE259243T1 (de) 2004-02-15
CA2358862A1 (en) 1997-05-29
PT866720E (pt) 2004-06-30
ATE455554T1 (de) 2010-02-15
ES2217327T3 (es) 2004-11-01
EP1285664B1 (de) 2010-01-20
NZ527007A (en) 2005-01-28
DE69638119D1 (de) 2010-03-11
MX9803992A (es) 1998-09-30
EP0866720A1 (de) 1998-09-30
JP2000500492A (ja) 2000-01-18
WO1997018833A1 (en) 1997-05-29
EP1285664A2 (de) 2003-02-26
DE69631544T2 (de) 2004-12-23

Similar Documents

Publication Publication Date Title
ATE259243T1 (de) Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
EA200300845A1 (ru) Модифицированные антитела и способы применения
EA200000652A1 (ru) Кристаллы глюкагоноподобного пептида 1
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
RO117177B1 (ro) Proteine recombinante, anti-obezitate, murine şi umane, secvenţă adn, care le codifică, procedeu de producere a proteinei şi conjugat cu acestea
GR3030141T3 (en) Diphtheria toxin receptor-binding region.
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
BR9915679A (pt) Composições e métodos para aumentar a mineralização óssea
ATE458815T1 (de) Homologe des nogo rezeptors
DE69632546D1 (de) Ob proteinderivate mit verlängerter halbwertzeit
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
HUP9901688A3 (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
DE69535274D1 (de) Verwendung eines menschlichen interleukin-11 rezeptors
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
DE69735039D1 (de) Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen
SE9803962D0 (sv) Nucleic acid encoding a nervous tissue sodium channel
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
AU7079300A (en) Compositions and methods for the treatment of immune related diseases
MD899G2 (ro) Procedeu de activizare a osteogenezei reparatorii

Legal Events

Date Code Title Description
8364 No opposition during term of opposition